Abstract Number: 2875 • 2016 ACR/ARHP Annual Meeting
Depressed Serum IgM Levels in SLE Are Restricted to Defined Subgroups
Background/Purpose: Natural IgM autoantibodies have been proposed to have protective properties, and decreased levels of IgM to phosphorylcholine (PC) in SLE are associated with higher…Abstract Number: 669 • 2016 ACR/ARHP Annual Meeting
RNA-Sequencing Reveals Sjogren’s Syndrome Anti-Ro Negative Patients Share Similar Pathways to Multiple Sclerosis Patients
Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune disease characterized by autoantibodies to Ro and/or La proteins and lymphocytic infiltration into exocrine glands. Multiple sclerosis (MS)…Abstract Number: 2668 • 2016 ACR/ARHP Annual Meeting
Real Time Sonoelastography in Primary Sjögren’s Syndrome Correlates with Morphological Ultrasonographic Features and Glandular Activity but Not with Glandular Fibrosis
Background/Purpose: Salivary gland ultrasonography is a highly specific tool for the diagnosis of primary Sjögren´s syndrome (PSS). Real time sonoelastography (RTS) is a novel imaging…Abstract Number: 3029 • 2016 ACR/ARHP Annual Meeting
Ultrasonography of Major Salivary Glands in Patients Suspected with Primary Sjögren’s Syndrome: Comparison with Salivary Gland Biopsy and Classification Criteria
Background/Purpose: Ultrasonography of major salivary glands (sUS) is applied in the diagnostic work-up of primary Sjögren's syndrome (pSS). This study aims to assess (i) the…Abstract Number: 672 • 2016 ACR/ARHP Annual Meeting
Sjogren Big Data Project: Influence of Geolocation on the Phenotypic Expression at Diagnosis in 8310 Patients (North-to-South Gradient)
Background/Purpose: To analyse the influence of geolocation (North-to-South gradient) on the clinical presentation of primary Sjögren syndrome (SjS) at diagnosis. Methods: The Big Data Sjögren…Abstract Number: 2670 • 2016 ACR/ARHP Annual Meeting
Work Disability in Newly Diagnosed Patients with Primary SjöGren’s Syndrome – a Population-Based Cohort Study
Background/Purpose: To study long-term work disability (WD) and possible predictors in newly diagnosed patients with primary Sjögren’s syndrome (pSS). Methods: 51 pSS patients…Abstract Number: 3031 • 2016 ACR/ARHP Annual Meeting
Rethinking Primary Sjögren’s Syndrome: Stratification By Clinical Phenotypes to Improve Understanding of Disease Pathogenesis, Trial Design, Clinical Management and Prospective Health Gains?
Background/Purpose: Primary SjšgrenÕs Syndrome (pSS) is a chronic autoimmune rheumatic disease causing a wide-range of symptoms including dryness, pain and fatigue. Individual patient experiences of…Abstract Number: 674 • 2016 ACR/ARHP Annual Meeting
Targeting Glandular IL-21-Production in Primary Sjogren′s Syndrome Patients By Immunomodulatory Treatment
Background/Purpose: Interleukin-21 plays a central role in plasma cell differentiation and germinal center (GC) formation and is likely involved in the pathogenesis of primary Sjögren’s…Abstract Number: 2671 • 2016 ACR/ARHP Annual Meeting
Impaired Bone Health in Patients with Primary Sjogren’s Syndrome
Background/Purpose: Patients were all Chinese from the outpatient and inpatient clinic of our hospital (Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China). Primary SS…Abstract Number: 3032 • 2016 ACR/ARHP Annual Meeting
Abnormalities in the Biological or Haematological Domain of the Essdai Predict an Increase in Systemic Disease Activity the Year after: 5-Year Data from the Prospective Multicenter Assess Cohort
Background/Purpose: Very limited data is available regarding predictors of systemic disease activity in primary Sjögren’s syndrome. The ESSDAI, the international systemic disease activity score of…Abstract Number: 11L • 2015 ACR/ARHP Annual Meeting
Preliminary Results of a Double-Blind Randomised Trial of Rituximab Anti-B-Cell Therapy in Patients with Primary Sjogrens Syndrome
Background/Purpose: Evidence from open-label and observational studies support anti-B-cell therapy in patients with primary Sjogren’s Syndrome (PSS). The TRACTISS trial aimed to determine the extent…Abstract Number: 632 • 2015 ACR/ARHP Annual Meeting
Isolated Atrioventricular Block of Unknown Origin in the Adult and Autoimmunity: Diagnostic and Therapeutic Considerations Exemplified By Three Anti-Ro/SSA-Associated Cases
Background/Purpose: Circulating anti-Ro/SSA antibodies may rarely affect the adult conduction-system. A direct autoantibody-mediated electrophysiological inhibition of cardiomyocyte calcium-channels (acquired form) or an ante-natal subclinical injury…Abstract Number: 1056 • 2015 ACR/ARHP Annual Meeting
Aquaporin Gene Therapy Corrects Bone Morphogenetic Protein 6 Associated Exocrine Gland Dysfunction in Mouse Model of Sjögren’s Syndrome
Background/Purpose: Loss of secretory epithelial function is a hallmark of primary Sjögren’s syndrome (pSS). Previously we reported that bone morphogenetic protein 6 (BMP-6) inhibits cell volume…Abstract Number: 2794 • 2015 ACR/ARHP Annual Meeting
A New Scoring System for Ultrasonographic Evaluation of Salivary Gland in Sjogren: Multireader Reliability
Background/Purpose: A new consensual scoring system for Ultrasonography (US) of the salivary gland in pSS is required and endorsed by an international group of experts…Abstract Number: 633 • 2015 ACR/ARHP Annual Meeting
Anti-Centromere Antibodies Are Associated with More Severe Exocrine Glandular Dysfunction in Primary Sjögren’s Syndrome: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Background/Purpose: Anti-centromere antibodies (ACA) define a subgroup of Sjögren’s syndrome (SS) patients who are often older, have more frequent Raynaud’s phenomenon, and a lower frequency…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 26
- Next Page »